<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00506207</url>
  </required_header>
  <id_info>
    <org_study_id>NCCCTS-06-166</org_study_id>
    <nct_id>NCT00506207</nct_id>
  </id_info>
  <brief_title>A Phase I Study of S-1 Plus Irinotecan and Oxaliplatin in Advanced Gastrointestinal Malignancy</brief_title>
  <acronym>TIROX</acronym>
  <official_title>A Phase I and Pharmacokinetic Study of S-1 Combined With Irinotecan and Oxaliplatin in Advanced Gastrointestinal Malignancy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Cancer Center, Korea</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Cancer Center, Korea</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is an open-label, single center, and a dose-escalating phase I study to determine&#xD;
      the maximal tolerated dose and the recommended dose of S-1 combined with&#xD;
      irinotecan/oxaliplatin in patients with unresectable or metastatic colorectal or gastric&#xD;
      carcinoma.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Dose level and escalating schedule are followings;&#xD;
&#xD;
        -  S-1 (level 1/2, 3/4, 5/6: 60, 70, 80 mg/m2/day) every 12-h p.o. on days 1(evening)-15&#xD;
           (morning)&#xD;
&#xD;
        -  Irinotecan (level 1,2/3, 4/5, 6: 120, 130, 140, 150 mg/m2) mixed in d5w or normal saline&#xD;
           500 ml iv over 90 min on day 1&#xD;
&#xD;
        -  Oxaliplatin 85 mg/m2 fixed dose mixed in d5w 250 ml iv infusion over 2-h on day 1&#xD;
&#xD;
      Treatment will be administered every 3 weeks. Start at dose level 1. Thereafter, dose level&#xD;
      2, 3, 4, 5, and 6. If dose-limiting toxicity (DLT) occurs at dose level 1, dose level at -1&#xD;
      will follow&#xD;
&#xD;
      Dose escalation will be continued until more than one-third of the patients in a given cohort&#xD;
      show dose-limiting toxicity (DLT) during treatment cycle 1. At least three patients will be&#xD;
      enrolled in each cohort. Before escalating to the next dose level, all three patients should&#xD;
      have received at least one treatment cycle. If none of the first three treated patients&#xD;
      develops DLT in the first cycle at a specific dose level, dose escalation will be continued.&#xD;
      If one of the first three treated patients develops DLT at any dose level, then three&#xD;
      additional patients are to be entered on the same dose level. If only one in six patients at&#xD;
      a given level experiences a DLT, escalation will proceed. The MTD is defined as the dose&#xD;
      level at which at least one-third of patients experienced a DLT. The RD for the subsequent&#xD;
      phase II study is defined as the preceding dose level before the MTD is attained.&#xD;
      Intra-patient dose escalation will not be permitted. Treatment will be continued in the&#xD;
      absence of disease progression or unacceptable toxicity with maximum 12 cycles. For purpose&#xD;
      of determining the MTD, only DLT occurring during the first cycle of therapy will be&#xD;
      considered.&#xD;
&#xD;
      DLTs are defined as any of following;&#xD;
&#xD;
        -  Grade 4 neutropenia lasting at least 7 days or grade 3 or 4 neutropenia associated with&#xD;
           fever  38.3C as single axillary temperature or 38 C for 1-h&#xD;
&#xD;
        -  Grade 4 thrombocytopenia&#xD;
&#xD;
        -  Grade 3 or 4 non-hematological toxicity except alopecia, and nausea/vomiting&#xD;
&#xD;
        -  Grade 3 or 4 nausea/vomiting not reduced to grade 1 with aggressive antiemetic support&#xD;
&#xD;
        -  Inability of the patient to take 75% of the planned chemotherapy dose during the&#xD;
           treatment period&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Active, not recruiting</last_known_status>
  <start_date>September 2006</start_date>
  <completion_date type="Anticipated">December 2009</completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Toxicity measured by NCICTC v.3</measure>
    <time_frame>During treatment</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Blood level of irinotecan and S-1 and their metabolites</measure>
    <time_frame>At 1st cycle</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Maximal response rate, progression-free survival, survival</measure>
  </secondary_outcome>
  <enrollment type="Actual">23</enrollment>
  <condition>Colorectal Neoplasm</condition>
  <condition>Gastric Neoplasm</condition>
  <condition>Secondary</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>S-1, Irinotecan, Oxaliplatin</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Histologically or cytologically confirmed unresectable or metastatic colorectal or&#xD;
             gastric carcinoma&#xD;
&#xD;
          -  Eastern Cooperative Oncology Group (ECOG) performance status 0-2&#xD;
&#xD;
          -  Measurable disease, according to the RECIST criteria or non-measurable disease&#xD;
             Measurable lesions&#xD;
&#xD;
          -  Previous adjuvant, palliative chemotherapy including 5-FU, oxaliplatin and irinotecan,&#xD;
             molecular targeted therapy and/or radiotherapy is allowed&#xD;
&#xD;
          -  Adequate major organ functions&#xD;
&#xD;
          -  Patients should sign a written informed consent before study entry&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Prior history of peripheral neuropathy&#xD;
&#xD;
          -  Inadequate cardiovascular&#xD;
&#xD;
          -  Serious concurrent infection or nonmalignant illness&#xD;
&#xD;
          -  Other malignancy within the past 3 years except non-melanomatous skin cancer or&#xD;
             carcinoma in situ of the cervix&#xD;
&#xD;
          -  Psychiatric disorder that would preclude compliance&#xD;
&#xD;
          -  Pregnant, nursing women or patients with reproductive potential without contraception&#xD;
&#xD;
          -  Patients receiving a concomitant treatment with drugs interacting with S-1 such as&#xD;
             flucytosine, phenytoin, or warfarin et al.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Kyung Hae Jung, M.D.Ph.D</last_name>
    <role>Principal Investigator</role>
  </overall_official>
  <location>
    <facility>
      <name>National Cancer Center Korea</name>
      <address>
        <city>Goyang</city>
        <state>Gyeonggi</state>
        <zip>410-769</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>July 2007</verification_date>
  <study_first_submitted>July 23, 2007</study_first_submitted>
  <study_first_submitted_qc>July 23, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 25, 2007</study_first_posted>
  <last_update_submitted>July 23, 2007</last_update_submitted>
  <last_update_submitted_qc>July 23, 2007</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 25, 2007</last_update_posted>
  <keyword>Gastrointestinal neoplasms</keyword>
  <keyword>Combination chemotherapy</keyword>
  <keyword>S-1</keyword>
  <keyword>Irinotecan</keyword>
  <keyword>Oxaliplatin</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasms</mesh_term>
    <mesh_term>Colorectal Neoplasms</mesh_term>
    <mesh_term>Stomach Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Oxaliplatin</mesh_term>
    <mesh_term>Irinotecan</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

